Patologen skal informeres om patientens brug af lasofoxifen ved vurdering af endometriehistology for at sikre en præcis diagnose af benign cystisk atrofi.
Pathologists should be made aware of a history of lasofoxifene use when assessing endometrial histology, to ensure an accurate diagnosis of benign cystic atrophy when present.